Vertex Pharmaceuticals Incorporated
VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of aā¦ read more
Healthcare
Biotechnology
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$455.50
Price-0.41%
-$1.86
1Y
Price
Market Cap
$116.892b
Large
Price/Earnings 3y Avg5y Avg
30x
Premium
Premium
Financials Overview
Key metrics over the past few years+44.1%
EBITDA Margin+35.2%
Net Profit Margin+37.0%
Free Cash Flow MarginRevenue
$11.723b
+6.4%
1y CAGR+9.5%
3y CAGR+11.6%
5y CAGREarnings
$3.675b
+786.2%
1y CAGR+226.8%
3y CAGR+180.5%
5y CAGREPS
$14.18
+781.7%
1y CAGR+225.0%
3y CAGR+179.4%
5y CAGRBook Value
$17.319b
$24.862b
Assets$7.544b
Liabilities$1.835b
DebtDebt to Assets
7.4%
0.4x
Debt to EBITDAFree Cash Flow
$3.337b
+522.3%
1y CAGR+127.2%
3y CAGR+111.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company